China Approves First Domestic Nine-Valent HPV Vaccine
The approval of Cecolin 9 marks a significant milestone in China's healthcare capabilities.
China has officially approved its first domestically developed nine-valent human papillomavirus (HPV) vaccine, named Cecolin 9. This development, announced by the state agency Xinhua, makes China the second country globally, after the United States, with the ability to independently produce high-valency HPV vaccines.
The vaccine has undergone five clinical trials since 2019, conducted across various regions in China, involving more than 11,000 volunteers aged 9 to 45 years.
Results have indicated that the vaccine provides strong protection against HPV types 16 and 18, the same types targeted by existing bivalent vaccines.
In addition to these types, Cecolin 9 is effective against five other HPV types: 31, 33, 45, 52, and 58. The vaccine shows a protection rate exceeding 98% for over 12 months, offering complete protection against cervical cancer.
According to the guidelines, only two doses are required for girls aged 9 to 17 to achieve immunity, while girls aged 18 to 26 require three doses.
A comparative study reported that the new Chinese vaccine provides immunity for at least 30 months, outperforming similar international vaccines.
As part of its public health strategy, China offered free HPV vaccinations to approximately 40% of girls aged 13 and 14 last year, as an effort to combat cervical cancer.
This initiative underscores the country’s commitment to enhancing healthcare and reducing cancer incidence among its young population.
The vaccine has undergone five clinical trials since 2019, conducted across various regions in China, involving more than 11,000 volunteers aged 9 to 45 years.
Results have indicated that the vaccine provides strong protection against HPV types 16 and 18, the same types targeted by existing bivalent vaccines.
In addition to these types, Cecolin 9 is effective against five other HPV types: 31, 33, 45, 52, and 58. The vaccine shows a protection rate exceeding 98% for over 12 months, offering complete protection against cervical cancer.
According to the guidelines, only two doses are required for girls aged 9 to 17 to achieve immunity, while girls aged 18 to 26 require three doses.
A comparative study reported that the new Chinese vaccine provides immunity for at least 30 months, outperforming similar international vaccines.
As part of its public health strategy, China offered free HPV vaccinations to approximately 40% of girls aged 13 and 14 last year, as an effort to combat cervical cancer.
This initiative underscores the country’s commitment to enhancing healthcare and reducing cancer incidence among its young population.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
